Evidence map›Paper›PMID 39349158›Full record

Trial reportJournal of cardiac failure2025

The Kansas City Cardiomyopathy Questionnaire in Relation to New York Heart Association Class.

Charles F Sherrod, John A Spertus, Kensey L Gosch, Andrew Wang, Perry M Elliott, Neal K Lakdawala, Matthew Reaney, Yue Zhong, Jenny Lam, Kathleen W Wyrwich and 1 more

Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of cardiac failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03470545 (A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03470545 phase3completednot on this map

A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

TypeinterventionalSponsorMyoKardia, Inc.Ran2018 to 2020Enrolled251ConditionsObstructive Hypertrophic CardiomyopathyArmsmavacamten, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Charles F SherrodUniversity of Missouri - Kansas City's Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute, Kansas City, Missouri.
John A SpertusUniversity of Missouri - Kansas City's Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute, Kansas City, Missouri.
Kensey L GoschUniversity of Missouri - Kansas City's Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute, Kansas City, Missouri.
Andrew WangDuke University School of Medicine, Durham, North Carolina.
Perry M ElliottUniversity College London and St Bartholomew's Hospital, London, United Kingdom.
Neal K LakdawalaBrigham and Women's Hospital, Boston, Massachusetts.
Matthew ReaneyIQVIA, Reading, United Kingdom.
Yue ZhongBristol Myers Squibb, Princeton, New Jersey.
Jenny LamBristol Myers Squibb, Princeton, New Jersey.
Kathleen W WyrwichBristol Myers Squibb, Princeton, New Jersey.
Andrew J SauerUniversity of Missouri - Kansas City's Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute, Kansas City, Missouri. Electronic address: asauer@saint-lukes.org.

Funding

CARDIOVASCULAR OUTCOMES RESEARCH TRAINING PROGRAMT32HL110837 · NHLBI · UNIVERSITY OF MISSOURI KANSAS CITY · PI JOHN A SPERTUS · 2012 to 2026
$5.0M
NHLBI NIH HHS T32 HL110837
6 · The paper itself

Abstract

backgroundIn order to identify candidacy and treatment response for patients with obstructive hypertrophic cardiomyopathy (oHCM), clinicians need an accurate means of assessing symptoms, function, and quality of life. While the New York Heart Association (NYHA) Classification is most often used for this purpose, the Kansas City Cardiomyopathy Questionnaire (KCCQ-23) is more accurate and sensitive to change, although less familiar to practicing clinicians. To support interpreting the KCCQ-23, we describe cross-sectional and longitudinal changes in KCCQ scores in the context of the NYHA.

methodsParticipants from the EXPLORER-HCM trial (NCT03470545) completed the KCCQ-23 and clinicians assigned NYHA classes at study visits. Participants were included if they had baseline and week 30 data for cross-sectional and longitudinal changes. Median KCCQ-23 scores were compared by NYHA class at baseline and week 30 and by change in NYHA class from baseline to week 30.

resultsCross-sectionally, the KCCQ-23 Overall Summary Scores (KCCQ-23 OSS) and Clinical Summary Scores (KCCQ-23 CSS) had an inverse relationship with the NYHA class at baseline and 30 weeks, with marked variations in KCCQ-23 scores among patients assigned to the same NYHA class. When improving from NYHA class II to I, the median changes in KCCQ-23 OSS and KCCQ-23 CSS were 10 (IQR 4, 22) and 8 (IQR 2, 20), respectively. The changes were larger when improving from NYHA class III to II and from NYHA class III to I.

conclusionKCCQ-23 scores are inversely related to NYHA classes, with significant variability within classes. Changes in scores are not linear, suggesting greater differences when patients move between NYHA Classes II and III than when moving between Classes I and II. These insights may help clinicians better understand cross-sectional and longitudinal changes in KCCQ scores.

Indexed as

Cardiomyopathy, HypertrophicQuality of LifeAgedCross-Sectional StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedSurveys and Questionnairescardiomyopathyheart failureHypertrophic cardiomyopathyNYHA Classquality of life

Identifiers

PMID39349158
PMCPMC11975531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.